PMCB PharmaCyte Biotech
- 1.620
- -0.430-20.98%
- 1.620
- 0.0000.00%
PharmaCyte Biotech News
PharmaCyte Biotech | 10-Q: Q1 2025 Earnings Report
PharmaCyte Biotech | 10-K: FY2024 Annual Report
Express News | MyMD Pharmaceuticals Inc - Secured $7 Mln in Commitments in Two Private Placement Funding Rounds Led by Strategic Investor, PharmaCyte Biotech, Inc
Express News | PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, a Biopharmaceutical Company Focused on Inflammatory Disease
PharmaCyte Biotech Interim CEO Silverman to Join Femasys Board >PMCB FEMY
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women's Health Innovator Femasys, Inc.
Femasys Secures $6.85M Additional Financing With Strategic Investment From Investors Led By PharmaCyte Biotech
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
PharmaCyte Completes Tender Offer to Purchase Shares
PharmaCyte Biotech Announces Final Results of Tender Offer
PharmaCyte Biotech Shares Up 13% to 52-Week High After Cash Tender Offer
Organogenesis, Arcturus Top Healthcare Gainers; ImmunityBio, Dynatronics Among Losers
12 Health Care Stocks Moving In Thursday's Pre-Market Session
PharmaCyte Biotech Completes $35M Private Placement >PMCB
Express News | PharmaCyte Biotech Puts Up Cash Tender Offer of 7.75M Shares for $3.25 Per Share >PMCB
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
Omega Therapeutics (NASDAQ:OMGA) & PharmaCyte Biotech (OTCMKTS:PMCBD) Head to Head Contrast
PharmaCyte Biotech (OTCMKTS:PMCBD) Stock Price Down 0.7%
PharmaCyte Biotech (OTCMKTS:PMCB) and Ocugen (NASDAQ:OCGN) Critical Review
Cortexyme (NASDAQ:CRTX) Versus PharmaCyte Biotech (OTCMKTS:PMCB) Critical Survey
Analysis
Price Target
No Data
No Data